Floatz logo

GEMOGENOVATUCEL-T

Neoplasms by Histologic Type

Gradalis, Inc.Cell therapyPhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
81/ 100

Competitive context

928 Active assets in the Neoplasms by Histologic Type cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Vinorelbine
Shi Yanxia
Phase 3BB
Relatlimab
Bristol-Myers Squibb
Phase 2BB
LIDOCAINE
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

GEMOGENOVATUCEL-T is also rated in:

ovarian cancerDormant
B
Indicative ·
57 / 100
View asset →
uterine cancerDormant
B
Indicative ·
57 / 100
View asset →
Ewing sarcomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →